Ocena postępowania diagnostycznego i terapeutycznego w ...

71. Harris NL, Jaffe ES, Stein H i wsp. A revised European-American classification of lymphoid
neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994; 84:
1361-92.
72. Jaffe ES, Stein H, Swerdlow SH i wsp. B-cell lymphoma, unclassifiable, with features
intermediate between diffuse large B-cell lymphoma and classical Hodgkina lymphoma. W:
Swerdlow SH, Campo E, Harris NL. (wyd.). WHO Classification of Tumours of
Haematopoietic and Lymphoid Tissues. Lyon: IARS Press 2008: 267-68.
73. Kupfer, eMedicine 2009, przegląd
74. Kowalczyk RJ, Dudkiewicz E, Balwierz W i wsp. Incidence of childhood cancers in Poland in
1995-1999. Med Sci Monit 2002; 8: CR587-CR590.
75. Kavan P, Kabickova E, Gajdos P i wsp. Treatment of pediatric B-cell non-Hodgkin’s
lymphomas at the Motol Hospital in Prague, Czech Republic: results based on the NHL BFM
90 protocols. Pediatr Hematol Oncol. 1999;16: 201-12.
76. Burkhardt B, Zimmermann M, Oschlies i wsp. The impact of age and gender on biology,
clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and
adolescence. British Journal of Hematology. 2005; 131: 39-49.
77. Coiffier B. Diffuse large cell lymphoma. Curr Opin Oncol. 2001; 13: 325-34.
78. Słomkowski M. Węzłowe postaci chłoniaków nieziarniczych złośliwych u osób dorosłych.
Post Nauk Med. 2003; 3-4: 61-70.
79. Cairo M, Krailo M, Morse M i wsp. Long-term follow-up of short intensive multiagent
chemotherapy without high-dose methotrexate (“Orange”) in children with advanced nonlymphoblastic
non-Hodkin’s lymphoma: a children’s cancer group report. Leukemia 2002;16:
594-600.
80. Patte C. Treatment of mature B-ALL and high grade B-NHL in children. Best Pract Res Clin
Hematol. 2003;15: 695-711.
81. Oschlies I, Klapper W, Zimmermann M i wsp. Diffuse large B-cell lymphoma in pediatric
patients belongs predominantly to the germinal-center type B-cell lymphomas: a
clinicopathologic analysis of cases included in the German BFM (Berlin-Frankfurt-Munster)
Multicenter Trial. Blood. 2006; 107: 4047-52.
82. Reiter A. Diagnosis and treatment of childhood Non-Hodgkin lymphoma. Hematology Am
Soc Hematol Educ Program. 2007: 285-96.
83. Reiter A i Klapper W. Recent advances in the understanding and management of diffuse large
B-cell lymphoma in children. Br J Haematol. 2008;142: 329-47.
84. Pession A, Masetti R. Rondelli R. Pediatric T-cell acute lymphoblastic leukemia and T-cell
lymphoblastic lymphoma therapy. Hematology Meeting Reports. 2009; 3: 111–14.
85. Taddesse-Heath L, Pittaluga S, Sorbara L, i wsp. Marginal zone B-cell lymphoma in children
and young adults. Am J Surg Pathol. 2003; 27: 522-31
86. Gross TG, Shiramizu B: Lymphoproliferative disorders related to immunodeficiencies. W:
Weinstein HJ, Hudson MM. (wyd.) Pediatric Lymphomas. Link MP. 2007.
87. Tran H, Nourse J, Hall S i wsp. Immunodeficiency-associated lymphomas. Blood Reviews.
2008; 22: 261–81.
88. Lyons S, Liebowitz D. The role of human viruses in the pathogenesis of lymphoma. Semin
Oncol. 1998; 25: 461-475.
89. Smedby KE, Hjalgrim H, Melbye M i wsp. Ultraviolet radiation exposure and risk of
malignant lymphomas. J Natl Cancer Inst. 2005; 97:199-209.
90. Münger K, Hayakawa H, Nguyen CL i wsp. Viral carcinogenesis and genomic instability. W:
Leon P. Bignold. (wyd.) Cancer: Cell Structures, Carcinogens and Genomic Instability.
Birkhäuser Verlag/Switzerland. 2006: 179-99.
91. Shaffer AL, Yu X, He Y i wsp. BCL-6 represses genes that function in lymphocyte
differentiation, inflammation, and cell cycle control. Immunity. 2000; 13: 199-212.
92. Hachem A, Gartenhaus RB. Oncogenes as molecular targets in lymphoma. Blood. 2005; 106:
1911-23.
93. van Heemst D, den Reijer PM, Westendorp RG. Ageing or cancer: a review on the role of
caretakers and gatekeepers. Eur J Cancer. 2007; 43: 2144-52.
140